<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="8" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font1" size="8" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font2" size="8" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font3" size="8" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font4" size="10" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font5" size="10" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font6" size="7" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font7" size="11" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font8" size="9" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font9" size="10" family="SymbolMT" color="#000000"/>
<text top="42" left="57" width="181" height="7" font="font0" id="p1_t1" reading_order_no="1" segment_no="0" tag_type="title">Breast Cancer Research Vol 7 No 1    Wang et al.<b>Breast Cancer Research</b></text>
<text top="735" left="18" width="19" height="8" font="font3" id="p1_t2" reading_order_no="0" segment_no="16" tag_type="text">R146</text>
<text top="85" left="57" width="240" height="9" font="font4" id="p1_t3" reading_order_no="2" segment_no="1" tag_type="text">[18,19]. The replicon RNA contained the replication/tran-<i>et al.</i></text>
<text top="97" left="57" width="240" height="9" font="font4" id="p1_t4" reading_order_no="3" segment_no="1" tag_type="text">scription genes of the parent virus, but the structural pro-</text>
<text top="109" left="57" width="241" height="9" font="font4" id="p1_t5" reading_order_no="4" segment_no="1" tag_type="text">tein genes were replaced by the gene for rat neu . From this<a href="">[18,19]. The repli</a>con RNA contained the replication/tran-</text>
<text top="120" left="57" width="240" height="9" font="font4" id="p1_t6" reading_order_no="5" segment_no="1" tag_type="text">plasmid construct, the replicon RNA is synthesized in the</text>
<text top="132" left="57" width="240" height="9" font="font4" id="p1_t7" reading_order_no="6" segment_no="1" tag_type="text">nucleus of the host cell and is transported to the cytoplasm</text>
<text top="144" left="57" width="240" height="9" font="font4" id="p1_t8" reading_order_no="7" segment_no="1" tag_type="text">for replication and transcription. The neu gene product is<i>neu</i></text>
<text top="156" left="57" width="241" height="9" font="font4" id="p1_t9" reading_order_no="8" segment_no="1" tag_type="text">produced at high levels in the cytosol. Since the structural</text>
<text top="167" left="57" width="241" height="9" font="font4" id="p1_t10" reading_order_no="9" segment_no="1" tag_type="text">protein genes from the parent virus are not encoded by the</text>
<text top="179" left="57" width="240" height="9" font="font4" id="p1_t11" reading_order_no="10" segment_no="1" tag_type="text">replicon, progeny infectious Sindbis virions are not gener-</text>
<text top="191" left="57" width="55" height="9" font="font4" id="p1_t12" reading_order_no="11" segment_no="1" tag_type="text">ated [20-22].</text>
<text top="214" left="57" width="240" height="9" font="font4" id="p1_t13" reading_order_no="12" segment_no="5" tag_type="text">Alternatives to Alphavirus replicon plasmid vaccines<i>neu </i></text>
<text top="226" left="57" width="240" height="9" font="font4" id="p1_t14" reading_order_no="13" segment_no="5" tag_type="text">[17,19,23-25] are Alphavirus-based virus-like replicon par-</text>
<text top="238" left="57" width="241" height="9" font="font4" id="p1_t15" reading_order_no="14" segment_no="5" tag_type="text">ticles (VRP). As already mentioned, the replicon RNA does</text>
<text top="250" left="57" width="240" height="9" font="font4" id="p1_t16" reading_order_no="15" segment_no="5" tag_type="text">not contain the structural genes from the parent virus. It is</text>
<text top="261" left="57" width="240" height="9" font="font4" id="p1_t17" reading_order_no="16" segment_no="5" tag_type="text">therefore a single-cycle, propagation-defective RNA and</text>
<text top="273" left="57" width="240" height="9" font="font4" id="p1_t18" reading_order_no="17" segment_no="5" tag_type="text">replicates only within the cell into which it is introduced. To<a href="">ed [20-22]</a>.</text>
<text top="285" left="57" width="240" height="9" font="font4" id="p1_t19" reading_order_no="18" segment_no="5" tag_type="text">generate VRP from an attenuated strain of the Alphavirus</text>
<text top="297" left="57" width="240" height="9" font="font4" id="p1_t20" reading_order_no="19" segment_no="5" tag_type="text">Venezuelan equine encephalitis virus (VEE), the replicon<a href="">[17,19,23-25] are</a> Alphavirus-based virus-like replicon par-</text>
<text top="308" left="57" width="241" height="9" font="font4" id="p1_t21" reading_order_no="20" segment_no="5" tag_type="text">RNA is packaged into particles by co-transfecting the rep-</text>
<text top="320" left="57" width="241" height="9" font="font4" id="p1_t22" reading_order_no="21" segment_no="5" tag_type="text">licon RNA and two separate helper RNAs, which together</text>
<text top="332" left="57" width="240" height="9" font="font4" id="p1_t23" reading_order_no="22" segment_no="5" tag_type="text">encode the full complement of VEE structural proteins [26].</text>
<text top="344" left="57" width="240" height="9" font="font4" id="p1_t24" reading_order_no="23" segment_no="5" tag_type="text">Although the VRP can infect target cells in culture or in</text>
<text top="355" left="57" width="240" height="9" font="font5" id="p1_t25" reading_order_no="24" segment_no="5" tag_type="text">vivo , and can express the foreign gene to a very high level,</text>
<text top="367" left="57" width="240" height="9" font="font4" id="p1_t26" reading_order_no="25" segment_no="5" tag_type="text">the VRP are defective since they lack critical portions of the</text>
<text top="379" left="57" width="240" height="9" font="font4" id="p1_t27" reading_order_no="26" segment_no="5" tag_type="text">VEE genome – they lack the VEE structural protein genes</text>
<text top="391" left="57" width="240" height="9" font="font4" id="p1_t28" reading_order_no="27" segment_no="5" tag_type="text">necessary to produce infectious virus particles capable of</text>
<text top="402" left="57" width="133" height="9" font="font4" id="p1_t29" reading_order_no="28" segment_no="5" tag_type="text">spreading to other cells [21,27].<a href=""> VEE structural proteins [26].</a></text>
<text top="426" left="57" width="240" height="9" font="font4" id="p1_t30" reading_order_no="29" segment_no="9" tag_type="text">Several reports have demonstrated that VRP are extremely</text>
<text top="438" left="57" width="241" height="9" font="font4" id="p1_t31" reading_order_no="30" segment_no="9" tag_type="text">effective vaccine vectors [28-39]. The VEE VRP vaccine<i>in</i></text>
<text top="449" left="57" width="240" height="9" font="font4" id="p1_t32" reading_order_no="31" segment_no="9" tag_type="text">vectors are particularly attractive because the VEE enve-<i>vivo</i></text>
<text top="461" left="57" width="240" height="9" font="font4" id="p1_t33" reading_order_no="32" segment_no="9" tag_type="text">lope glycoproteins target the VRP to cells of lymphoid tis-</text>
<text top="473" left="57" width="241" height="9" font="font4" id="p1_t34" reading_order_no="33" segment_no="9" tag_type="text">sue [40], because they can be administered multiple times</text>
<text top="485" left="57" width="240" height="9" font="font4" id="p1_t35" reading_order_no="34" segment_no="9" tag_type="text">[39], because they induce both cellular and humoral</text>
<text top="496" left="57" width="240" height="9" font="font4" id="p1_t36" reading_order_no="35" segment_no="9" tag_type="text">immune responses, and because pre-existing immunity to</text>
<text top="508" left="57" width="241" height="9" font="font4" id="p1_t37" reading_order_no="36" segment_no="9" tag_type="text">VEE in humans should not be problematic since the inci-<a href="">[21,27].</a></text>
<text top="520" left="57" width="123" height="9" font="font4" id="p1_t38" reading_order_no="37" segment_no="9" tag_type="text">dence of VEE infection is low.</text>
<text top="543" left="57" width="240" height="9" font="font4" id="p1_t39" reading_order_no="38" segment_no="13" tag_type="text">In the current study, we sought to determine whether vac-<a href="">[28-39]. The VEE VRP </a>vaccine</text>
<text top="555" left="57" width="240" height="9" font="font4" id="p1_t40" reading_order_no="39" segment_no="13" tag_type="text">cination with VEE-derived VRP containing the gene for</text>
<text top="567" left="57" width="240" height="9" font="font4" id="p1_t41" reading_order_no="40" segment_no="13" tag_type="text">HER2/ neu would inhibit tumor growth in prevention models</text>
<text top="579" left="57" width="240" height="9" font="font4" id="p1_t42" reading_order_no="41" segment_no="13" tag_type="text">in which HER2/ neu -expressing tumor cells had been<a href="">[40]</a>, because they can be administered multiple times</text>
<text top="590" left="57" width="240" height="9" font="font4" id="p1_t43" reading_order_no="42" segment_no="13" tag_type="text">injected either into a mammary fat pad or intravenously. We<a href="">[39</a>], because they induce both cellular and humoral</text>
<text top="602" left="57" width="240" height="9" font="font4" id="p1_t44" reading_order_no="43" segment_no="13" tag_type="text">also sought to determine whether vaccination could pre-</text>
<text top="614" left="57" width="240" height="9" font="font4" id="p1_t45" reading_order_no="44" segment_no="13" tag_type="text">vent spontaneous tumorigenesis in HER2/ neu transgenic</text>
<text top="625" left="57" width="241" height="10" font="font4" id="p1_t46" reading_order_no="45" segment_no="13" tag_type="text">mice. VRP- neu vaccination induced antigen-specific CD8 +</text>
<text top="637" left="57" width="240" height="9" font="font4" id="p1_t47" reading_order_no="46" segment_no="13" tag_type="text">T-cell and IgG responses that corresponded with the lack</text>
<text top="649" left="57" width="240" height="9" font="font4" id="p1_t48" reading_order_no="47" segment_no="13" tag_type="text">of tumor growth in both tumor models. In light of the clinical</text>
<text top="661" left="57" width="240" height="9" font="font4" id="p1_t49" reading_order_no="48" segment_no="13" tag_type="text">benefit of trastuzumab, a safe and effective vaccine that</text>
<text top="673" left="57" width="240" height="9" font="font4" id="p1_t50" reading_order_no="49" segment_no="13" tag_type="text">can induce cellular and humoral immunity, VRP- neu war-<i>neu </i></text>
<text top="684" left="57" width="98" height="9" font="font4" id="p1_t51" reading_order_no="50" segment_no="13" tag_type="text">rants clinical evaluation.</text>
<text top="85" left="315" width="121" height="10" font="font7" id="p1_t52" reading_order_no="51" segment_no="2" tag_type="title">Materials and methods</text>
<text top="97" left="315" width="122" height="8" font="font8" id="p1_t53" reading_order_no="52" segment_no="3" tag_type="title">Tumor cell line and reagents<i>neu</i></text>
<text top="109" left="315" width="241" height="9" font="font4" id="p1_t54" reading_order_no="53" segment_no="4" tag_type="text">The A2L2 cell line that expresses high levels of rat HER2/</text>
<text top="120" left="315" width="240" height="9" font="font5" id="p1_t55" reading_order_no="54" segment_no="4" tag_type="text">neu has been previously described in detail [17]. The A2L2</text>
<text top="132" left="315" width="241" height="9" font="font4" id="p1_t56" reading_order_no="55" segment_no="4" tag_type="text">cell line has consistently expressed high levels of HER2/</text>
<text top="144" left="315" width="241" height="9" font="font5" id="p1_t57" reading_order_no="56" segment_no="4" tag_type="text">neu for more than 5 years and consistently induces tumors</text>
<text top="156" left="315" width="240" height="9" font="font4" id="p1_t58" reading_order_no="57" segment_no="4" tag_type="text">in Balb/c mice when injected into a mammary fat pad or<i>neu </i></text>
<text top="167" left="315" width="241" height="9" font="font4" id="p1_t59" reading_order_no="58" segment_no="4" tag_type="text">intravenously. The A2L2 cell line was maintained in Eagle's</text>
<text top="179" left="315" width="240" height="9" font="font4" id="p1_t60" reading_order_no="59" segment_no="4" tag_type="text">MEM containing 5% FCS, sodium pyruvate, nonessential</text>
<text top="191" left="315" width="240" height="9" font="font4" id="p1_t61" reading_order_no="60" segment_no="4" tag_type="text">amino acids, L-glutamine, and vitamins (GIBCO, Carlsbad,<i>neu </i></text>
<text top="203" left="315" width="240" height="9" font="font4" id="p1_t62" reading_order_no="61" segment_no="4" tag_type="text">CA, USA). The monolayer cultures were subdivided at</text>
<text top="214" left="315" width="241" height="9" font="font4" id="p1_t63" reading_order_no="62" segment_no="4" tag_type="text">approximately 75% confluence by treatment for 1–3 min</text>
<text top="226" left="315" width="191" height="9" font="font4" id="p1_t64" reading_order_no="63" segment_no="4" tag_type="text">with 0.25% trypsin and 0.02% EDTA at 37°C.</text>
<text top="250" left="315" width="118" height="8" font="font8" id="p1_t65" reading_order_no="64" segment_no="6" tag_type="title">Virus-like replicon particles</text>
<text top="261" left="315" width="241" height="9" font="font4" id="p1_t66" reading_order_no="65" segment_no="7" tag_type="text">The pSV2- neu plasmid containing the gene for rat HER2/</text>
<text top="273" left="315" width="240" height="9" font="font5" id="p1_t67" reading_order_no="66" segment_no="7" tag_type="text">neu was provided by Dr Mien-Chie Hung (The University of</text>
<text top="285" left="315" width="240" height="9" font="font4" id="p1_t68" reading_order_no="67" segment_no="7" tag_type="text">Texas MD Anderson Cancer Center, Houston, TX, USA).<i>neu </i></text>
<text top="297" left="315" width="241" height="9" font="font4" id="p1_t69" reading_order_no="68" segment_no="7" tag_type="text">VEE VRP were constructed at AlphaVax, Inc. (Research Tri-</text>
<text top="308" left="315" width="241" height="9" font="font4" id="p1_t70" reading_order_no="69" segment_no="7" tag_type="text">angle Park, NC, USA) according to the published proce-</text>
<text top="320" left="315" width="241" height="9" font="font4" id="p1_t71" reading_order_no="70" segment_no="7" tag_type="text">dure [26]. Control VRP containing the gene for A/PR/8/34<b>Materials and methods</b></text>
<text top="332" left="315" width="241" height="9" font="font4" id="p1_t72" reading_order_no="71" segment_no="7" tag_type="text">influenza hemagglutinin (HA) were also prepared following<b>Tumor cell line and reagents</b></text>
<text top="344" left="315" width="241" height="9" font="font4" id="p1_t73" reading_order_no="72" segment_no="7" tag_type="text">the same procedure. VRP preparations were screened in a</text>
<text top="355" left="315" width="240" height="9" font="font4" id="p1_t74" reading_order_no="73" segment_no="7" tag_type="text">sensitive in vitro Vero cell cytopathic effect assay for the<i>neu </i></text>
<text top="367" left="315" width="241" height="9" font="font4" id="p1_t75" reading_order_no="74" segment_no="7" tag_type="text">detection of replication competent virus. Prior to their use<a href="">in detail [17]. </a>The A2L2</text>
<text top="379" left="315" width="241" height="9" font="font4" id="p1_t76" reading_order_no="75" segment_no="7" tag_type="text">in these studies, the preparations were shown to be devoid</text>
<text top="391" left="315" width="171" height="9" font="font4" id="p1_t77" reading_order_no="76" segment_no="7" tag_type="text">of detectable replication competent virus.<i>neu </i></text>
<text top="414" left="315" width="66" height="8" font="font8" id="p1_t78" reading_order_no="77" segment_no="8" tag_type="title">Flow cytometry</text>
<text top="426" left="315" width="240" height="9" font="font4" id="p1_t79" reading_order_no="78" segment_no="10" tag_type="text">A2L2 cells were incubated for 1 hour at 37°C with either</text>
<text top="438" left="315" width="241" height="9" font="font4" id="p1_t80" reading_order_no="79" segment_no="10" tag_type="text">immune serum or control serum diluted in PBS. FITC-</text>
<text top="449" left="315" width="240" height="9" font="font4" id="p1_t81" reading_order_no="80" segment_no="10" tag_type="text">labeled goat anti-mouse IgG diluted 1:1000 in PBS was</text>
<text top="461" left="315" width="240" height="9" font="font4" id="p1_t82" reading_order_no="81" segment_no="10" tag_type="text">added to the cells and incubation was continued for 1 hour</text>
<text top="473" left="315" width="240" height="9" font="font4" id="p1_t83" reading_order_no="82" segment_no="10" tag_type="text">at 37°C. The cells were washed three times in PBS and</text>
<text top="485" left="315" width="240" height="9" font="font4" id="p1_t84" reading_order_no="83" segment_no="10" tag_type="text">were  analyzed  by  flow  cytometry using an EPICS Profile</text>
<text top="496" left="315" width="221" height="9" font="font4" id="p1_t85" reading_order_no="84" segment_no="10" tag_type="text">Analyzer (Beckman Coulter, Inc., Fullerton, CA, USA).</text>
<text top="520" left="315" width="21" height="8" font="font8" id="p1_t86" reading_order_no="85" segment_no="11" tag_type="title">Mice<b>Virus-like replicon particles</b></text>
<text top="532" left="315" width="240" height="9" font="font4" id="p1_t87" reading_order_no="86" segment_no="12" tag_type="text">Female Balb/c mice, aged 6–8 weeks, were obtained from</text>
<text top="543" left="315" width="240" height="9" font="font4" id="p1_t88" reading_order_no="87" segment_no="12" tag_type="text">the Frederick Cancer Research Facility (Frederick, MD,<i>neu </i></text>
<text top="555" left="315" width="240" height="9" font="font4" id="p1_t89" reading_order_no="88" segment_no="12" tag_type="text">USA). Mice were allowed to acclimate for at least 1 week</text>
<text top="567" left="315" width="240" height="9" font="font4" id="p1_t90" reading_order_no="89" segment_no="12" tag_type="text">before use. Six-week-old MMTV-c- neu transgenic mice<i>neu </i></text>
<text top="579" left="315" width="241" height="9" font="font4" id="p1_t91" reading_order_no="90" segment_no="12" tag_type="text">were obtained from Charles River Laboratories Inc. (Wilm-</text>
<text top="590" left="315" width="240" height="9" font="font4" id="p1_t92" reading_order_no="91" segment_no="12" tag_type="text">ington, MA, USA). This strain of mice is called the 'Onco-</text>
<text top="602" left="315" width="240" height="9" font="font4" id="p1_t93" reading_order_no="92" segment_no="12" tag_type="text">mouse' by Charles River Laboratories due to the</text>
<text top="614" left="315" width="241" height="9" font="font4" id="p1_t94" reading_order_no="93" segment_no="12" tag_type="text">spontaneous generation of breast cancer. These mice are</text>
<text top="626" left="315" width="241" height="9" font="font4" id="p1_t95" reading_order_no="94" segment_no="12" tag_type="text">of the FVB/N strain, and the transgene is the 'activated' rat<a href="">[26]</a>. Control VRP containing the gene for A/PR/8/34</text>
<text top="637" left="315" width="231" height="9" font="font4" id="p1_t96" reading_order_no="95" segment_no="12" tag_type="text">c- neu oncogene preceded by the MMTV promoter [41].</text>
<text top="661" left="315" width="92" height="8" font="font8" id="p1_t97" reading_order_no="96" segment_no="14" tag_type="title">Vaccination with VRP</text>
<text top="673" left="315" width="241" height="9" font="font4" id="p1_t98" reading_order_no="97" segment_no="15" tag_type="text">Mice were vaccinated subcutaneously in the hind foot pad</text>
<text top="681" left="315" width="241" height="12" font="font4" id="p1_t99" reading_order_no="98" segment_no="15" tag_type="text">with VRP suspended in 50 µ l normal saline. Repeat vacci-<i>in vitro </i></text>
<text top="696" left="315" width="240" height="9" font="font4" id="p1_t100" reading_order_no="99" segment_no="15" tag_type="text">nations, when administered, were performed using alter-</text>
<text top="708" left="315" width="240" height="9" font="font4" id="p1_t101" reading_order_no="100" segment_no="15" tag_type="text">nate hind feet. Tail vein blood was removed and tumor</text>
<text top="720" left="315" width="240" height="9" font="font4" id="p1_t102" reading_order_no="101" segment_no="15" tag_type="text">challenge performed 2 weeks after the final vaccination.</text>
</page>
</pdf2xml>
